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waBACKGROUND In patients with resistant hypertension (RH) and obstructive sleep apnea (OSA), the blood pressure
response to continuous positive airway pressure (CPAP) treatment is highly variable and could be associated with
differential micro–ribonucleic acid (miRNA) proﬁles. Currently, no available methods exist to identify patients who will
respond favorably to CPAP treatment.
OBJECTIVES The aim of this study was to identify plasma miRNA proﬁles that predict blood pressure responses to
CPAP treatment.
METHODS Cardiovascular system–focused circulating miRNA expression was evaluated in plasma samples using an
84-miRNA array among patients with RH and OSA at baseline and after 3 months of adherent CPAP use. Pathway analysis
and miRNA target gene enrichment were performed in silico. Plasma levels of peptides and hormones related to
cardiovascular function were also measured.
RESULTS The OSA responder group exhibited blood pressure decreases exceeding the observed median (>4.5 mm Hg)
after CPAP, which were not present in the nonresponder group (#4.5 mm Hg) (p < 0.01). Three miRNAs provided a
discriminatory predictive model for such a favorable blood pressure response to CPAP (area under the curve: 0.92;
p ¼ 0.01). Additionally, CPAP treatment signiﬁcantly altered a total of 47 plasma miRNAs and decreased aldosterone-
to-renin ratios in the responder group (p ¼ 0.016) but not in the nonresponder group.
CONCLUSIONS A singular pre-CPAP treatment cluster of 3 plasma miRNAs predicts blood pressure responses to CPAP
treatment in patients with RH and OSA. CPAP treatment is accompanied by changes in cardiovascular system–related
miRNAs that may potentially inﬂuence the risk for cardiovascular disease among patients with OSA and RH. (Effect
of Continuous Positive Airway Pressure [CPAP] Treatment in the Control of Refractory Hypertension; NCT00616265)
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1024C ardiovascular disease (CVD) is theleading cause of death throughoutthe world. Among all risk factors
associated with CVD development, hyper-
tension is likely the most important; it is
also among the most treatable cardiovascular
risk factors (1). Between 12% and 27% of
all patients with hypertension are consid-
ered to have resistant hypertension (RH)
(2), deﬁned as blood pressure (BP) higher
than therapeutic goals (i.e., average systolic
BP $130 mm Hg, average diastolic BP $80
mm Hg, or both) despite concurrent use of
at least 3 antihypertensive agents prescribed
at doses that provide optimal beneﬁt, with
1 of these drugs ideally being a diureticagent (3). Patients with RH are approximately 50%
more likely to experience cardiovascular events than
patients with hypertension but not RH, and the inci-
dence of RH is anticipated to increase in the coming
years (4).SEE PAGE 1033Obstructive sleep apnea (OSA), a common disorder
that affects approximately 10% of the middle-age
population (5), is associated with increased CVD and
overall mortality risks (6–9). OSA is a common cause
of systemic hypertension and should be suspected in
patients with hypertension (10–13), particularly those
with RH (14,15). Indeed, more than 70% of patients
with RH have OSA (16). Although continuous positive
airway pressure (CPAP) treatment reduces BP levels
in patients with OSA (17–24), its beneﬁcial effects are
related to patient adherence as well as to baseline
BP levels (25,26). However, BP responses are highly
variable, even when adherent use of CPAP is
documented, with some patients exhibiting major
reductions in BP (>10 mm Hg) and others showing
either unchanged or worsening BP levels (16,25,27). In
fact, 25% to 30% of patients who use CPAP treatment
for >4 h/night do not experience a positive effect on
BP (25,26). The underlying causes of patient vari-
ability in response to continuous adherent use of
CPAP are unknown. More important, no tools are
available to date that enable clinicians to identify
those patients who will respond favorably to CPAP
treatment (i.e., reduced BP levels).de Neumología, Fundació Catalana de Neumología, Agència de Ge
ón Biomédica en Red de Enfermedades Respiratorias. The auth
the contents of this paper to disclose.
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received April 10, 2015; revised manuscript received June 12, 20Micro-ribonucleic acids (miRNAs) are a class of
small (19- to 25-nucleotide), noncoding RNAs that
regulate gene expression at the post-transcriptional
level by binding to a target messenger RNA, thereby
leading to either degradation or translational repres-
sion (28). Evidence suggests that miRNAs control
development and are critically involved in many
biological processes related to health and disease,
including CVD (29–31). Consequently, miRNAs have
emerged as major protagonists for managing CVD in
an era of evolving precision medicine.
We hypothesized that among patients with RH and
OSA, a singular cardiovascular system–focusedmiRNA
biomarker proﬁle might reliably discriminate those
patients with favorable BP responses to CPAP. Addi-
tionally, we posited that adherence to CPAP treatment
might modify the miRNA proﬁles and plasma levels
of peptides and hormones related to cardiovascular
function. Some of these study results have been pre-
viously reported in abstract form (32,33).
METHODS
Study participants were part of a larger multicenter,
randomized, controlled trial (NCT00616265) con-
ducted at 24 Spanish teaching hospitals to evaluate
the effect of 3 months of CPAP treatment on the BP
levels of patients with RH and OSA; the patient char-
acteristics have been provided in detail elsewhere
(26). In this study, we included male patients who
used CPAP for at least 4 h/day. CPAP adherence was
objectively examined on the basis of the number of
hours of CPAP use per day, according to the device’s
internal clock. Patients with reductions in mean BP
greater than the observed median of 4.5 mm Hg were
classiﬁed as responders to CPAP treatment.
To identify plasma miRNA proﬁles that predict BP
response to CPAP treatment, we screened an initial
group of 8 subjects with the best and 8 subjects with
theworst BP responses to adherent CPAP usewhowere
matched for age, sex, ethnicity, body mass index, and
participant center (Figure 1). The initial set of differ-
entially expressed miRNAs from these experiments
was then used in a subsequent complete training set
(n ¼ 24), divided equally between responders and
nonresponders, enabling ﬁnal selection of the mini-
mum number of miRNAs that speciﬁcally differentiatestió d’Ajuts Universitaris i de Recerca, and Centro de
ors have reported that they have no relationships
ntin Fuster.
15, accepted June 19, 2015.
FIGURE 1 Study Flow
Male patients (n = 71) with resistant hypertension and OSA who were
treated with CPAP from the HIPARCO randomized clinical trial were
assessed for eligibility.
A total of 33 patients were excluded.
Thirteen patients used CPAP for <4 h per 
day.
No samples were available for 20 patients.
Training set (n = 24)
Study sample (n = 38)
Validation set (n = 14)
Nonresponders
(n = 12)*†‡
Nonresponders
(n = 6)
Responders
(n = 8)
Responders
(n = 12)*†‡
Patients with resistant hypertension and obstructive sleep apnea (OSA) were divided into training and validation sets and further divided for
study on the basis of favorable blood pressure (BP) response (responders) and unfavorable response (nonresponders) to adherent use of
continuous positive airway pressure (CPAP) treatment. *Eight patients each with the best and worst BP responses to CPAP were used to screen
the initial micro–ribonucleic acid (miRNA) candidate set. †Twelve nonresponders and 12 responders were used as the training set, which
included the previous 8 patients per group. ‡Five patients each with the best and worst BP responses were used to evaluate the effect of CPAP
treatment on miRNA proﬁles.
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1025responders and nonresponders. This latter ﬁnal set
of miRNAs was then further validated in an indepen-
dent group of patients (n ¼ 14) that constituted the
validation set. Additionally, to assess the effect of
adherent use of CPAP on cardiovascular system–
focused miRNA biomarker proﬁling, we evaluated
5 patients with the best and 5 patients with the
worst BP responses to CPAP at baseline and after
3 months of adherent CPAP use. Finally, to evaluate
the impact of CPAP treatment on the plasma levels of
hormones and proteins functionally related to car-
diovascular functions, all patients (n ¼ 38) were eval-
uated. The ethics committee of each participating
center approved the study, and patients provided
written informed consent.
Venous blood samples were obtained from patients
between 8 and 10 AM after fasting overnight. Total
RNA, including miRNA, was isolated from the plasma
using the miRNeasy Mini Kit column-based system
according to the manufacturer’s instructions (Qia-
gen, Valencia, California). We used miRNA arrays
(84 miRNAs) speciﬁc for the human cardiovascular
system (Qiagen) using samples from patients with
RH and OSA. Quantitative real-time reverse tran-
scription polymerase chain reaction (qRT-PCR) ana-
lyses were performed using an ABI 7500 (AppliedBiosystems, Foster City, California). Complementary
deoxyribonucleic acid synthesis was performed
using a miScript SYBR Green PCR Kit (Qiagen). Addi-
tional details are provided in the Online Appendix.
The Web-based computational tool DIANA-mirPath
version 2.1 (34) was used to predict the target
genes and altered Kyoto Encyclopedia of Genes and
Genomes pathways of the differentially expressed
miRNAs. Myeloid-related protein 8/14 and adropin
have been previously identiﬁed as atherogenic
markers that are related to endothelial dysfunction.
Additionally, renin and aldosterone play an impor-
tant role in regulating blood volume and sys-
temic vascular resistance. Plasma concentrations of
myeloid-related protein 8/14, adropin, renin, and
aldosterone were measured. For additional method-
ological information, see the Online Appendix.
STATISTICAL ANALYSIS. Comparability between the
responders and nonresponders was assessed using
the Mann-Whitney U test for quantitative character-
istics and the Fisher exact test for qualitative vari-
ables. A multivariate logistic regression model was
ﬁtted to the training set to predict the response to
CPAP. Variables maximizing the discrimination abil-
ity of the model, as measured with the area under
TABLE 1 Baseline Characteristics
Nonresponders
(n ¼ 18)
Responders
(n ¼ 20)
p
Value
Change in MBP after CPAP treatment
(pre- minus post-CPAP), mm Hg*
0.25 (5 to 2.5) 11 (7.5 to 14.1) —
Men 18 (100) 20 (100) 1.00
Age, yrs 60 (52 to 66) 54 (50.8 to 63) 0.14
BMI, kg/m2 32 (30.1 to 34) 32.1 (30.7 to 37.6) 0.39
Neck perimeter, cm 42.5 (42 to 43.8) 44 (42.0 to 46) 0.49
Apnea-hypopnea index, events/h 34.5 (22.2 to 47.8) 48.5 (31.5 to 59) 0.12
TSat90 6 (1.5 to 11.2) 7 (2.00 to 27) 0.17
Epworth Sleepiness Scale score 9 (6.5 to 12) 8 (5.00 to 9) 0.26
CPAP mean use, h/day 5.5 (4.5 to 6) 5.5 (4.88 to 6.5) 0.87
24-h MBP, mm Hg 113 (107 to 114) 118 (111 to 122) 0.057
SBP, mm Hg 142 (136 to 150) 147 (138 to 152) 0.41
DBP, mm Hg 82.5 (74.2 to 85.8) 88.5 (82.5 to 94) 0.026
Nocturnal BP pattern 0.76
Dipper 4 (22.2) 7 (35)
Nondipper 9 (50) 9 (45)
Riser 5 (27.8) 4 (20)
Stroke 1 (5.56) 2 (10) 1.00
Coronary heart disease 4 (22.2) 3 (15) 0.68
Peripheral arterial disease 1 (5.56) 2 (10) 1.00
Diabetes 7 (38.9) 9 (45) 0.96
Dyslipidemia 11 (61.1) 13 (65) 1.00
Tobacco use, pack-yrs 0 (0 to 28.8) 0 (0 to 29.8) 0.6
Years since diagnosis of resistant
hypertension
12 (11.5 to 22) 9 (4 to 15.5) 0.077
Number of systemic hypertension drugs 3 (3 to 3.75) 3.5 (3 to 4) 0.25
Calcium-channel blockers 10 (55.6) 15 (75.0) 0.358
Angiotensin II receptor blockers 13 (72.2) 11 (55.0) 0.446
b-blockers 9 (50.0) 13 (65.0) 0.544
Angiotensin-converting enzyme inhibitors 5 (27.8) 5 (25.0) 1.00
a1-blockers 5 (27.8) 5 (25.0) 1.00
Renin blockers 2 (11.1) 1 (5.00) 0.595
Type of diuretic agent 0.44
None 2 (11.1) 0 (0)
Thiazides/xipamide no loop
diuretic agents
7 (38) 11 (55)
Loop diuretic agents without thiazides 8 (44.4) 7 (35)
Potassium-sparing/antialdosterone 0 (0) 0 (0)
Thiazides and loop diuretic agents 1 (5.56) 2 (10)
Values are median (interquartile range) or n (%). *Descriptive values show changes in MBP in each group after
CPAP treatment; p value not calculated because this was a quantitative variable used to deﬁne the groups.
BMI ¼ body mass index; BP ¼ blood pressure; CPAP ¼ continuous positive airway pressure; DBP ¼ diastolic
blood pressure; IQR ¼ interquartile range; MBP ¼ mean blood pressure; SBP ¼ systolic blood pressure; TSat90 ¼
night time spent with oxygen saturation less than 90%.
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1026the curve (AUC), were included in the model if they
exhibited statistically signiﬁcant contributions ac-
cording to the likelihood ratio test. Possible cutoff
points for each quantitative variable were selected
from those dividing the sample into 2 categories, re-
sponders and nonresponders. The Hosmer-Lemeshow
test was used to test model calibration, and the
continuous net reclassiﬁcation index was used to
determine the inclusion of those variables without
statistically signiﬁcant contributions to the multivar-
iate logistic regression model but that improved itsAUC. The ﬁnal model was translated into an easy-to-
use scoring system (the sum of the integer values),
the HIPARCO-Score. Sensitivity and speciﬁcity were
estimated for each possible cutoff point. The exact
binomial distribution was used to estimate 95% con-
ﬁdence intervals (CIs) for the proportions. The Mann-
Whitney U test was used to compare changes in
miRNA expression after CPAP treatment (pre-post)
between responders and nonresponders. False-
discovery rate–adjusted p values were determined
to adjust for the performance of multiple paired
comparisons. After CPAP treatment, differences in
clinical variables were assessed using a paired non-
parametric Wilcoxon test for quantitative variables
and a symmetry test (generalized McNemar test) for
qualitative variables. The Mann-Whitney U test was
used to compare baseline (pre) levels, post–CPAP
treatment (post) levels, and changes (pre-post) of
peptides and hormones related to cardiovascular
function between responders and nonresponders. R
software (R Project for Statistical Computing, Vienna,
Austria) was used for statistical analysis, with a sig-
niﬁcance level of 0.05. Post-hoc estimation of the
detectable effect size using the available sample size,
statistical power of 0.80, and a signiﬁcance level
of 0.05 was performed using G*Power 3.1 software
(35). (Additional details are provided in the Online
Appendix and Online Figure 1.)
RESULTS
Patient characteristics were similar at baseline
(Table 1), with the exception of diastolic BP, which
was signiﬁcantly higher in responders compared with
nonresponders (p ¼ 0.026). Online Table 1 presents
the comparable characteristics between the re-
sponders and nonresponders in the training set, with
the exception of the time since RH diagnosis, which
was signiﬁcantly shorter in responders (p ¼ 0.041).
In the validation set (Online Table 2), responders
and nonresponders exhibited similar characteristics,
except that the percentage of patients receiving
calcium-channel blockers was signiﬁcantly higher in
the responder group (p ¼ 0.015).
Eight patients with the best BP responses to CPAP
and 8 patients with the worst responses were used
to screen candidate miRNAs for the detection of
favorable BP responses to CPAP. After miRNA PCR
array-based expression analysis, a subset of 8 dif-
ferentially expressed miRNAs (based on relative
quantiﬁcation of >1.65 or <1/1.65 when normalizing
using at least 3 housekeeping miRNAs) was selected
for subsequent analysis: miR-7-5p, miR-29a-3p,
miR-92a-3p, miR-100-5p, miR-144-3p, miR-150-5p,
TABLE 2 Multivariate Logistic Regression Models
Model M2* Model M3†
Estimate OR p Value Estimate OR p Value
dCt (miR-378a-3p) <2.6 3.01 (1.47) 20.3 0.041 2.39 (1.46) 10.9 0.102
dCt (miR-486-5p) >7.1 2.47 (1.25) 11.8 0.048 2.67 (1.36) 14.4 0.049
dCt (miR-100-5p) #0.4 — — — 1.50 (1.32) 4.5 0.256
*Model M2 includes the 2 micro–ribonucleic acids contributing signiﬁcantly to the identiﬁcation of responders. †Model M3 adds miR-100-5p to model M2.
OR ¼ odds ratio.
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1027miR-378a-3p, and miR-486-5p. Reproducibility of
these results was then conﬁrmed in an independent
assay (qRT-PCR). The microarray and qRT-PCR results
were normalized using the same control (SNORD95),
and all miRNA microarray data agreed with the
qRT-PCR data, except for miR-29a-3p, which exhi-
bited unreliable expression values, with no signiﬁ-
cant intraclass correlation coefﬁcient (p ¼ 0.25)
(Online Table 3). The average SNORD95 Ct values
were similar for the plasma collected from the re-
sponders (30.9  2.5) and nonresponders (30.7  1.0)
(p > 0.05), thus conﬁrming the applicability of this
gene as a normalizer. qRT-PCR conﬁrmed array ﬁnd-
ings in the complete training set of 24 patients.
Logistic regression models were generated using
the training set of 24 patients to evaluate the
discriminatory power of the combination of differ-
entially expressed miRNAs to identify favorable BPFIGURE 2 Received-Operating Characteristic Curve for the HIPARCO
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1028and was therefore added to the ﬁnal model (model M3
in Table 2). Figure 2A shows the receiver-operating
characteristic curve for the model M3 discrimination
in the training set (AUC: 0.88; 95% CI: 0.75 to
1.00). Model M3 showed good calibration (Hosmer-
Lemeshow goodness-of-ﬁt p ¼ 0.979) (Table 2). This
model was validated in an independent group
(validation set), yielding an AUC of 0.92 (95% CI:
0.79 to 1.00; Hosmer-Lemeshow p ¼ 0.991)
(Figure 2B). By translating the logistic regression
model into a score by adding 1 if dCt (miR-
100-5p) #0.4, 2 if dCt (miR-378a-3p) <2.6, and 3 if
dCt (miR-486-5p) >7.1, we were able to simplify
the model’s use by producing a simple numeric
score (the HIPARCO-Score, ranging from 0 to 6) that
predicts the probability of favorable BP response to
adherent CPAP use (Table 3).
Among the patients with RH and OSA, adherent
use of CPAP treatment for 3 months resulted in de-
creases in mean BP (p < 0.001), systolic and diastolic
BP (p ¼ 0.008), and Epworth Sleepiness Scale score
(p < 0.001). No signiﬁcant changes were observed in
the number of antihypertensive agents taken per
patient (Online Table 6). We evaluated the miRNA
biomarker proﬁles in 5 patients with the best and
worst BP responses to CPAP treatment; adherent use
differentially altered the expression of 47 of the 84
cardiovascular system–focused miRNAs evaluated
(with a false–discovery rate multitesting-corrected
p value of <0.05) (Online Table 7). In favorable BP re-
sponders, most of the cardiovascular system–focused
miRNAs were down-regulated after adherent CPAP
treatment (Figure 3, Online Figure 2).
The enrichment analysis, including the 7 miRNAs
conﬁrmed to be differentially expressed at base-
line in BP responders and nonresponders, revealed
2,868 putative target genes and 42 pathways (Online
Table 8, Online Figure 3). Enrichment analysis, which
included the 47 miRNAs that were found to beHIPARCO-Score to Estimate Favorable BP Response
Observed
Probability
Predicted
Probability
Expected
Frequency
Observed
Frequency Total
0% 6% 0.34 0 6
50% 21% 0.42 1 2
50% 46% 1.85 2 4
67% 75% 2.24 2 3
67% 80% 2.38 2 3
100% 90% 1.81 2 2
100% 98% 1.95 2 2
table, including observed and predicted frequencies and probabilities, showing no
ack of ﬁt (with a resulting Hosmer-Lemeshow test p ¼ 0.979).differentially expressed after treatment with CPAP,
revealed 8,069 putative target genes and 67 pathways
(Online Table 9, Online Figure 4). In both analyses, the
most frequently enriched pathways were categorized
under biological processes connectedwith cancer, CVD,
and signal transduction, as well as with the endocrine
and nervous systems (Online Tables 8 and 9).
Decreases in aldosterone-to-renin ratios were
signiﬁcantly greater in the responder group (p¼0.016)
(Online Table 10) and were positively correlated
with the change in mean BP values after adherent
CPAP use (r ¼ 0.46; p ¼ 0.001) (Online Table 11).
A complementary analysis identifying changes in
mean BP that were most signiﬁcantly associated with
plasma levels of peptides and hormones is presented
in the Online Appendix (Online Tables 12 and 13).
DISCUSSION
A singular cluster of miRNAs functionally associated
with the cardiovascular system appears to speciﬁcally
discriminate patients with RH and OSAwho respond to
CPAP treatment with favorable decreases in mean BP
from those who do not (Central Illustration). The mea-
surement of a speciﬁc cluster of miRNAs enabled
generation of a predictive screening tool (HIPARCO-
Score) to identify those responders. The present study
also demonstrated that adherent CPAP treatment is
associated with changes in circulating cardiovascular
system–related miRNAs that could potentially inﬂu-
ence the risk for developing CVD in patients with RH
and OSA. Finally, we showed that CPAP treatment
signiﬁcantly decreases the aldosterone-to-renin ratio
in responders (Online Figure 5).
Adherent use of CPAP treatment results in a me-
dian decrease in 24-h mean BP of 4.5 mm Hg. Studies
of different antihypertensive drug regimens have
demonstrated that small reductions of BP ranging
from 1 to 2 mm Hg may be clinically signiﬁcant on
the basis of an associated reduction in the risks for
cardiovascular and cerebrovascular events. More-
over, responders exhibited a median BP decrease of
11 mm Hg, a reduction associated with a dramatic
reduction in the relative risk for stroke, coronary
heart disease, heart failure, major cardiovascular
events, cardiovascular death, and total mortality (36).
A very large degree of variability in the effect of
CPAP treatment on BP levels has been observed,
likely because of the multifactorial nature of systemic
hypertension. This variability has led to increased
interest in prospectively identifying subgroups of
patients who will more likely beneﬁt from CPAP
treatment. Previous studies have reported that 25%
to 30% of patients with OSA with adequate adherence
FIGURE 3 Unsupervised Hierarchical Clustering of the miRNA Microarray
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This heat map illustrates the differential micro–ribonucleic acid (miRNA) expression after
continuous positive airway pressure (CPAP) compared with baseline for each patient. This
set was constructed using a random forest plot to identify the miRNAs with maximum
importance according to the Gini index. The heat map colors range from red (or negative
ddCt, denoting increased expression after CPAP) to blue (or positive ddCt, denoting
decreased expression after CPAP) to white (no change in ddCt after CPAP), without scaling
by row or column. The bottom of the image presents the mean blood pressure change for
each subject after 3 months of adherent CPAP use. Dendrograms show hierarchical clus-
tering representing the similarities and dissimilarities in expression proﬁles among subjects
and among miRNAs. NR ¼ nonresponder; R ¼ responder.
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1029to CPAP (>4 h/night) did not exhibit BP reductions
(25,26). In this study, we showed that the HIPARCO-
Score enabled the correct identiﬁcation of 100% of
the patients who adequately responded to adherent
CPAP use. Additionally, the HIPARCO-Score identi-
ﬁed 50% of the patients who did not show any
BP reduction despite adherent CPAP use and there-
fore will require complementary intervention for
BP control. Diagnostic and personalized therapeutic
decision-making tools are needed to manage sleep
apnea and to effectively predict responses to
adherent CPAP use. Reinforcement approaches aim-
ing to guarantee adequate CPAP adherence may
be particularly important for these patients. Deter-
mination of miRNAs can be performed in tertiary
university hospitals at a low cost ($35 to $50).
Adherent CPAP use was associated with changes
in the expression of 47 of the 84 miRNAs evaluated.
Changes in the miRNA proﬁle differed signiﬁ-
cantly between responders and nonresponders. In
responders, CPAP treatment was associated with an
overall decrease in cardiovascular system–focused
circulating miRNAs; nonresponders demonstrated
no change or even an increase in the expression levels
of some of the circulating miRNAs post-CPAP treat-
ment. The unsupervised hierarchical clustering of the
miRNA microarray revealed a set of miRNAs with
expression changes that differed signiﬁcantly be-
tween the 2 response groups. Our study design
allowed us to compare the circulating miRNA proﬁle
of each patient before and after OSA resolution,
enabling the incorporation of interindividual vari-
ability into the analyses, which increased the statis-
tical power to detect expression changes after
adherent CPAP use. This process provided an oppor-
tunity to implement bioinformatic procedures and
identify enriched putative biological pathways in
response to CPAP. Most of these pathways for the
group of miRNAs with altered expression levels post-
CPAP are related to CVD and cancer. Each miRNA
regulates a large number of distinct target genes.
Selected miRNAs are emerging as pivotal modulators
of mammalian cardiovascular development and dis-
eases, such as cardiac ﬁbrosis, arrhythmia, myocar-
dial infarction, cardiac hypertrophy, cardiomyopathy
(37), and cancer (additional information is provided
in the Online Appendix). These results may indicate
an association between long-term adherent CPAP use
and a reduced incidence of CVD.
However, categorization of the enriched biological
pathways also yielded somewhat unexpected results.
Indeed, we observed that most of the enriched bio-
logical pathways for the miRNAs that exhibited
altered expression levels after CPAP treatment fellunder categories of biological processes that were
closely connected to cancer. Recent studies have
reported an association between OSA and cancer
incidence (38) and mortality rates (39). Moreover,
CENTRAL ILLUSTRATION Predicting BP Response to CPAP Treatment: Box Plot of Responders and Nonresponders
Sánchez-de-la-Torre, M. et al. J Am Coll Cardiol. 2015; 66(9):1023–32.
Box plot of micro–ribonucleic acid (miRNA)–normalized expression in patients with obstructive sleep apnea and resistant hypertension (RH) with favorable
(responders) and unfavorable (nonresponders) blood pressure (BP) responses to adherent use of continuous positive airway pressure (CPAP) at baseline and
post-CPAP treatment. The data points represent the median of each miRNA-normalized expression for each group of patients. To facilitate interpretation,
we present the dCt values because high Ct values are indicative of lower expression. Consequently, positive values indicate high expression normalized to
the housekeeping gene SNORD95. Data were obtained from the 5 patients with the best and 5 patients with the worst BP responses to CPAP (deﬁned as a
greater than 4.5 mm Hg change in mean BP after treatment). In patients with RH, there was a signiﬁcantly different post-CPAP treatment trend in miRNA
expression. Thus, whereas nonresponders showed a signiﬁcant increase in miRNA expression, responders showed an inverse behavior, reducing miRNA
expression.
Sánchez-de-la-Torre et al. J A C C V O L . 6 6 , N O . 9 , 2 0 1 5
Predicting Blood Pressure Response to CPAP Treatment S E P T E M B E R 1 , 2 0 1 5 : 1 0 2 3 – 3 2
1030
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Many patients
with RH have OSA, and CPAP treatment reduces BP in patients
with these conditions, but responses are variable even among
those who adhere to treatment. A cluster of microRNAs related
to cardiovascular function reliably discriminates those patients
with favorable BP responses to CPAP.
TRANSLATIONAL OUTLOOK: Further studies are needed to
elucidate the mechanisms mediating the relationship between
these microRNAs, OSA, RH, and the response to CPAP.
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1031a recent study demonstrated that effective CPAP
treatment is associated with transcriptional suppres-
sion of cancer-related pathways (40). Thus, even
though our selected miRNA array was a priori focused
on cardiovascular functions, further in silico explo-
ration of gene targets of differentially expressed
miRNAs revealed gene candidates involved in onco-
logical processes as well.
Finally, we observed that in patients with RH
and OSA, CPAP treatment was associated with
changes in plasma levels of the aldosterone-renin
system. High aldosterone-to-renin ratios, indicative
of hyperaldosteronism, were signiﬁcantly decreased
post-CPAP in responders. Aldosterone secretion is
elevated in patients with systemic hypertension.
Moreover, increased secretion of aldosterone and
renin during repetitive apneic events may play a role
in regulating BP levels and ﬂuid balance in OSA (41).
Previous studies have demonstrated that plasma
aldosterone is positively correlated with OSA severity
only in subjects with RH (41). The results of the
present study further suggest that adherent CPAP
use decreases the aldosterone-to-renin ratio only
in patients with RH and OSA whose BP levels signif-
icantly decrease after CPAP treatment.
STUDY LIMITATIONS. The major strength of the pre-
sent study is its multicenter prospective design.
However, this study had several potential limitations.
First, we examined only male patients, and our con-
clusions cannot be extrapolated to women. In fact, we
performed a goodness-of-ﬁt test for the HIPARCO-
Score for women, which revealed poor calibration
and poor discrimination (Online Appendix).
Second, the present study did not include
numerous patients who refused blood sampling, and
thus possible relevant relationships cannot be
extrapolated to those patients. However, this study
allowed us to detect high-magnitude associations
with favorable BP responses to adherent CPAP use.
CONCLUSIONS
A singular cluster of cardiovascular system–related
functional miRNAs was identiﬁed that speciﬁcallydifferentiates between patients with RH and OSA
with favorable BP responses to CPAP treatment and
those with unfavorable responses. The HIPARCO-
Score is an easy-to-use and highly predictive clin-
ical practice tool for identifying favorable BP
responders to CPAP treatment among patients with
RH and OSA; further studies using this score are
therefore warranted. Additionally, adherent CPAP
treatment is associated with changes in circulating
cardiovascular system–related miRNAs that may
affect the risk for developing CVD in patients with
RH and OSA. Finally, CPAP treatment was signiﬁ-
cantly associated with decreases in aldosterone-
to-renin ratios that were restricted to favorable BP
responders to CPAP.
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